EUCTR2006-003912-23-GB进行中（未招募）1 期
A Phase IIa, double-blind, placebo-controlled, randomised, parallel-group study, to investigate the safety, tolerability and anxiolytic effect of the mGluR5 negative allosteric modulator ADX10059 in patients with dental anxiety undergoing dental treatment.
Addex Pharmaceuticals SA0 个研究点目标入组 50 人开始时间: 2006年9月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients aged 18 to 65 years inclusive.
- •2.Patients who score between 12 and 23 (inclusive) on a Modified Dental anxiety scale at screening.
- •3.Patients who have a scheduled appointment for an elective dental procedure (dental treatment is not to last more than 1.5 hours).
- •4.Ability to communicate well with the study staff and to comply with the requirements of the entire study.
- •5.Patients who provide written informed consent to participate in this study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Current diagnosis of significant co-existing psychiatric disorder i.e. one that requires medication such as antidepressant, antipsychotic medications and anxiolytics.
- •2.Food intake less than two hours before dosing (i.e. the patient has fasted for 2 hours prior to dosing).
- •3.Patients with known clinically significant allergy or known hypersensitivity to drugs that, in the opinion of the Investigator, may affect the patient’s safety.
- •4.Patients who have significant abnormal laboratory parameters at Screening, in particular, liver or renal functions tests greater than twice the upper limit of normal or any other clinically significant biochemical or haematological abnormality as determined by the Investigator.
- •5.Women who are pregnant or breast-feeding. Female patients who are of child-bearing potential must be using adequate contraceptive methods (e.g. oral contraceptive, double-barrier method, intra-uterine device [IUD], intra-muscular hormonal contraceptive), and have a negative pregnancy test at Screening (Visit 1) and prior to dosing on the Treatment Day (Visit 2).
- •6.Patients who are regular users of recreational drugs (in particular benzodiazepines, amphetamine, metamphetamine, cocaine and opiates) or any sedatives, and who have used them within 14 days before Screening (Visit 1).
- •7.Patients with a history of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study.
- •8. Patients taking sodium valproate or valproic acid or patients who have taken either of these within the last 30 days.
- •9. Administration of any investigational drug up to 30 days before study entry.
研究者
相似试验
进行中（未招募）
1 期
Placebo-controlled, double blind, randomised research in several centres to investigate the effect, safety and tolerability of a monoclonal antibody in patients with severe acute myocardial infarction.Treatment of ST-elevated myocardial infarction (STEMI) after percutaneous intervention (PCI)MedDRA version: 20.0 Level: SOC Classification code 10007541 Term: Cardiac disorders System Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0 Level: LLT Classification code 10064346 Term: STEMI System Organ Class: 10007541 - Cardiac disordersEUCTR2018-003676-12-SEAthera Biotechnologies AB80
进行中（未招募）
1 期
Placebo-controlled, double blind, randomised research in several centres to investigate the effect, safety and tolerability of a monoclonal antibody in patients with severe acute myocardial infarction.Treatment of ST-elevated myocardial infarction (STEMI) after percutaneous intervention (PCI)MedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10064346Term: STEMISystem Organ Class: 10007541 - Cardiac disordersEUCTR2018-003676-12-NLAthera Biotechnologies AB80
进行中（未招募）
1 期
Placebo-controlled, double blind, randomised research in several centres to investigate the effect, safety and tolerability of a monoclonal antibody in patients with low artery flow despite percutan coronar intervention (PCI) for acute myocardial infarction.EUCTR2018-003676-12-DKAthera Biotechnologies AB80
进行中（未招募）
不适用
A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-week Study to Investigate the Safety and Efficacy of Oral SPP635 450 mg Once Daily in Patients With Mild to Moderate Hypertensiomild to moderate hypertensionEUCTR2006-004176-13-DESpeedel Pharma Ltd.
进行中（未招募）
不适用
A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Fourfold Cross-Over Study to Investigate the Glucose Lowering Effects of Dextromethorphan and Amantadine in Subjects with Type 2 Diabetes Mellitus (T2DM) after an Oral Glucose Tolerance TestEUCTR2011-002986-39-DEProfil Institut für Stoffwechselforschung GmbH